Shibolet Oren, Karmeli Fanny, Eliakim Rami, Swennen Erwin, Brigidi Patrizia, Gionchetti Paulo, Campieri Massimo, Morgenstern Sara, Rachmilewitz Daniel
Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem.
Inflamm Bowel Dis. 2002 Nov;8(6):399-406. doi: 10.1097/00054725-200211000-00004.
Clinical and experimental data suggest an important role for intestinal microflora in the pathogenesis of inflammatory bowel disease, and probiotics have been shown to ameliorate pouchitis. We evaluated the effect of different preparations of probiotic bacteria on experimental colitis in rats.
Rats were treated daily intragastrically with two probiotic preparations, VSL#3 or strain GG (LGG), 7 days before induction of colitis and for another week thereafter. Colitis was induced by intracolonic administration of either dinitrobenzene sulfonic acid (DNBS) or iodoacetamide. Rats were killed 7 days after induction of colitis, the colon isolated, washed, weighed, lesion area measured, and mucosa processed for determination of myeloperoxidase (MPO) and nitric oxide synthase (NOS) activities and prostaglandin E2 (PGE2) generation.
In rats cotreated with VSL#3 or LGG and iodoacetamide, there was a significant decrease in the lesion area, 98 +/- 37 mm and 142 +/- 43 mm, respectively, as compared with 342 +/- 66 mm in the control group. Colonic wet weight significantly decreased to 1.3 +/- 0.1 g/10 cm and 1.4 +/- 0.1 g/10 cm, respectively, as compared with 1.7 +/- 0.1 g/10 cm. There was also a significant decrease in PGE2 generation, MPO, and NOS activities in the VSL#3 and LGG treatment groups. Presence of VSL#3 bacteria in the rat's colon was confirmed by culture and polymerase chain reaction (PCR) amplification. Neither probiotic preparation had an effect on the extent of colonic damage in DNBS-induced colitis.
Both VSL#3 and LGG significantly ameliorated colitis induced by the sulfhydryl-blocker iodoacetamide, but had no effect on the immune-mediated DNBS-induced colitis. The results suggest a possible role for sulfhydryl compounds in the protective effect of probiotic bacteria, and support their use in patients with inflammatory bowel disease.
临床及实验数据表明肠道微生物群在炎症性肠病发病机制中起重要作用，且已证实益生菌可改善袋炎。我们评估了不同益生菌制剂对大鼠实验性结肠炎的影响。
在诱导结肠炎前7天及之后的另一周，每天给大鼠灌胃两种益生菌制剂，即VSL#3或菌株GG（LGG）。通过结肠内给予二硝基苯磺酸（DNBS）或碘乙酰胺诱导结肠炎。诱导结肠炎7天后处死大鼠，分离结肠，冲洗、称重，测量损伤面积，并对黏膜进行处理以测定髓过氧化物酶（MPO）、一氧化氮合酶（NOS）活性及前列腺素E2（PGE2）生成量。
在与VSL#3或LGG及碘乙酰胺共同处理的大鼠中，损伤面积显著减小，分别为98±37mm和142±43mm，而对照组为342±66mm。结肠湿重分别显著降至1.3±0.1g/10cm和1.4±0.1g/10cm，而对照组为1.7±0.1g/10cm。VSL#3和LGG治疗组的PGE2生成量、MPO及NOS活性也显著降低。通过培养及聚合酶链反应（PCR）扩增证实大鼠结肠中存在VSL#3细菌。两种益生菌制剂对DNBS诱导的结肠炎的结肠损伤程度均无影响。
VSL#3和LGG均显著改善了由巯基阻断剂碘乙酰胺诱导的结肠炎，但对免疫介导的DNBS诱导的结肠炎无影响。结果表明巯基化合物在益生菌的保护作用中可能起作用，并支持其在炎症性肠病患者中的应用。
